{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:03:39Z","timestamp":1784073819121,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Improved new medications for systemic sclerosis-related Raynaud\u2019s phenomenon (SSc-RP) are badly needed and better objective outcomes are required to enable this. Thermography imaging of hand cold-challenge offers potential as an outcome measure. To ensure standardisation between pre- and post-dose cold challenge assessments, it is important to understand the length of time required for patients to recover back to baseline finger temperatures after initial cold challenge. The aim of this study was to determine whether patients with SSc-RP would recover baseline finger temperatures within a 2-h period. Patients with SSc-RP underwent cold-challenge alongside thermography-imaged baseline and post-cold challenge recovery for 2 h. Twenty patients were recruited, eight (40%) had all eight fingers recover to baseline within 2 h, 13 (65%) had more than one finger recover. The median (IQR) time to maximum temperature was 48.43 (33.58\u201369.38) minutes. This study indicates that most patients will have one or more fingers recover within an hour. Even in those with established SSc it is reasonable to repeat cold challenge with a minimum one-hour interval in clinical trials, enabling pre- and post-dose cold challenges on the same day.<\/jats:p>","DOI":"10.1038\/s41598-026-50510-5","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:44:02Z","timestamp":1778762642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing post-cold challenge recovery of thermography as a potential outcome measure in trials of SSc-related Raynaud\u2019s phenomenon"],"prefix":"10.1038","volume":"16","author":[{"given":"Abigail Aika","family":"Ndosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Dinsdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Mandzuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane L.","family":"Herrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea K.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"50510_CR1","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","volume":"71","author":"FM Meier","year":"2012","unstructured":"Meier, F. M. et al. Update on the profile of the EUSTAR cohort: An analysis of the EULAR scleroderma trials and research group database. Ann. Rheum. Dis. 71, 1355\u20131360 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"50510_CR2","doi-asserted-by":"crossref","unstructured":"Kumar, K., Maundrell, A., Proudman, S. Epidemiology of Raynaud\u2019s phenomenon. Raynaud\u2019s phenomenon from pathogenesis to management. In: Wigley FM, Herrick AL, Flavahan NA (eds.). Springer, 2024: 25\u201340.","DOI":"10.1007\/978-3-031-52581-0_3"},{"key":"50510_CR3","first-page":"S103","volume":"30","author":"JD Pauling","year":"2012","unstructured":"Pauling, J. D., Shipley, J. A., Harris, N. D. & McHugh, N. J. Use of infrared thermography as an endpoint in therapeutic trials of Raynaud\u2019s phenomenon and systemic sclerosis. Clin. Exp. Rheumatol. 30, S103\u2013S115 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"50510_CR4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/rheumatology\/keac426","volume":"62","author":"AL Herrick","year":"2023","unstructured":"Herrick, A. L. et al. A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud\u2019s. Rheumatology 62, 824\u2013828 (2023).","journal-title":"Rheumatology"},{"key":"50510_CR5","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","volume":"42","author":"M Dziadzio","year":"1999","unstructured":"Dziadzio, M. et al. Losartan therapy for Raynaud\u2019s phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 42, 2646\u20132655 (1999).","journal-title":"Arthritis Rheum."},{"key":"50510_CR6","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/rheumatology\/ket421","volume":"53","author":"AL Herrick","year":"2014","unstructured":"Herrick, A. L. et al. A double-blind, randomized, placebo-controlled crossover trial of the \u03b12C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis. Rheumatology 53, 948\u2013952 (2014).","journal-title":"Rheumatology"},{"key":"50510_CR7","first-page":"iii45","volume":"suppl_3","author":"N Selenko-Gebauer","year":"2006","unstructured":"Selenko-Gebauer, N., Duschek, N., Minimair, G., Stingl, G. & Karlhofer, F. Successful treatment of patients with severe secondary Raynaud\u2019s phenomenon with the endothelin receptor antagonist bosentan. Rheumatology suppl_3, iii45\u2013iii48 (2006).","journal-title":"Rheumatology"},{"key":"50510_CR8","first-page":"keae049","volume":"30","author":"G Tornling","year":"2024","unstructured":"Tornling, G. et al. A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud\u2019s. Rheumatology 30, keae049 (2024).","journal-title":"Rheumatology"},{"key":"50510_CR9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","volume":"40","author":"B Coleiro","year":"2001","unstructured":"Coleiro, B. et al. Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 40, 1038\u20131043 (2001).","journal-title":"Rheumatology"},{"key":"50510_CR10","doi-asserted-by":"crossref","unstructured":"Wilkinson, J., Seibold, J.R., Statistical design and reporting of randomised controlled trials for Raynaud\u2019s phenomenon. Raynaud\u2019s phenomenon from pathogenesis to management. In: Wigley FM, Herrick AL, Flavahan NA (eds.). Springer 2024: 297\u2013307.","DOI":"10.1007\/978-3-031-52581-0_16"},{"issue":"6","key":"50510_CR11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/art.40457","volume":"70","author":"JD Wilkinson","year":"2018","unstructured":"Wilkinson, J. D. et al. A multicenter study of the validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: Outcome measures for systemic sclerosis-related Raynaud\u2019s phenomenon. Arthritis Rheumatol. 70(6), 903\u2013911 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"50510_CR12","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: An American college of rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum. 65, 2737\u20132747. https:\/\/doi.org\/10.1002\/art.38098 (2013).","journal-title":"Arthritis Rheum."},{"key":"50510_CR13","doi-asserted-by":"publisher","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","volume":"3","author":"S Bellando-Randone","year":"2021","unstructured":"Bellando-Randone, S. et al. Progression of patients with Raynaud\u2019s phenomenon to systemic sclerosis: A five-year analysis of the European scleroderma trial and research group multicentre, longitudinal registry study for very early diagnosis of systemic sclerosis (VEDOSS). Lancet Rheumatol 3, e834\u2013e843 (2021).","journal-title":"Lancet Rheumatol"},{"key":"50510_CR14","first-page":"1630","volume":"30","author":"PA Merkel","year":"2003","unstructured":"Merkel, P. A. et al. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J. Rheumatol. 30, 1630\u20131647 (2003).","journal-title":"J. Rheumatol."},{"key":"50510_CR15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.semarthrit.2021.04.005","volume":"51","author":"N Maltez","year":"2021","unstructured":"Maltez, N. et al. Developing a core set of outcome measure domains to study Raynaud\u2019s phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020. Semin. Arthritis Rheum. 51, 640\u2013643 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"50510_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152208","volume":"61","author":"N Maltez","year":"2023","unstructured":"Maltez, N. et al. Domain reporting in systemic sclerosis-related Raynaud\u2019s phenomenon: An OMERACT scoping review. Semin. Arthritis Rheum. 61, 152208 (2023).","journal-title":"Semin. Arthritis Rheum."},{"key":"50510_CR17","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3899\/jrheum.180818","volume":"46","author":"JD Pauling","year":"2019","unstructured":"Pauling, J. D., Reilly, E., Smith, T. & Frech, T. M. Factors influencing Raynaud condition score diary outcomes in systemic sclerosis. J. Rheumatol. 46, 1326\u20131334 (2019).","journal-title":"J. Rheumatol."},{"key":"50510_CR18","doi-asserted-by":"crossref","unstructured":"Merkel, P.A., Herlyn, K., Martin, R.W., Anderson, J.J., Mayes, M.D., Bell, P. et al, Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud\u2019s phenomenon. Arthritis Rheum. 46, 2410\u201320 (2002)","DOI":"10.1002\/art.10486"},{"issue":"1","key":"50510_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/acr.25452","volume":"77","author":"L Taylor","year":"2025","unstructured":"Taylor, L. et al. Impact of season, environmental temperature, and humidity on Raynaud phenomenon in an Australian systemic sclerosis cohort. Arthritis Care Res 77(1), 61\u201368 (2025).","journal-title":"Arthritis Care Res"},{"issue":"10","key":"50510_CR20","doi-asserted-by":"publisher","first-page":"e684","DOI":"10.1016\/S2665-9913(24)00189-9","volume":"6","author":"G Virgili-Gervais","year":"2024","unstructured":"Virgili-Gervais, G. et al. The association of outdoor temperature and self-reported Raynaud\u2019s phenomenon severity among people with systemic sclerosis: A scleroderma patient-centered intervention network cohort study. Lancet Rheumatol. 6(10), e684\u2013e692 (2024).","journal-title":"Lancet Rheumatol."},{"issue":"8","key":"50510_CR21","first-page":"1699","volume":"42","author":"G Dinsdale","year":"2024","unstructured":"Dinsdale, G. et al. No seasonal trends in referrals for vascular investigations: Insight into the diagnosis of Raynaud\u2019s phenomenon and systemic sclerosis. Clin. Exp. Rheumatol. 42(8), 1699\u20131700 (2024).","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50510-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50510-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50510-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:08:23Z","timestamp":1784070503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50510-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50510"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50510-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ALH has received consultancy fees from AbbVie, Arena, Boehringer Ingelheim, Camurus, Galderma, Gesynta Pharma and Janssen, speaker fees from Janssen, and research funding from Gesynta Pharma. AKM has received consultancy fees from Arena and Gesynta Pharma. Other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22122"}}